Dr Olah is the Group Director of Bioanalytical Research at Bristol-Myers Squibb Company (NJ, USA) where his research interests center on the development of comprehensive multiple component bioanalytical methods to quantify all types of drug modalities and endogenous proteins and biomarkers in numerous biological fluids. His team integrates intricate sample collection procedures, analyte enrichment techniques, and liquid chromatography mass spectrometry (LC–MS) detection to maximize data generation in in vivo studies. These bioanalytical strategies support all drug discovery programs at BMS and the Biocon-BMS-Research-Center (BBRC) in Bangalore, India.
Dr Olah is a graduate of Princeton University (BA Chemistry; NJ, USA) and the University of Pennsylvania (PhD Biological Chemistry; PA, USA). His career started at Merck Research Laboratories, included time at DuPont Pharmaceuticals, and now has been at BMS for the past 19 years. Dr Olah has over 100 publications and has presented at numerous international universities and conferences throughout his career.
What three things would you take if you were stranded on a desert island?
Binoculars, telescope, writing materials
If you weren’t a bioanalysts what would you be?
College basketball coach
What is your favorite city?
Cape May Point, NJ
Why have you decided to become a Zone Leader?
Promote scientific discussion within the bioanalytical community
2018 White Paper on Recent Issues in Bioanalysis: focus on immunogenicity assays by hybrid LBA/LCMS and regulatory feedback (Part 2 – PK, PD & ADA assays by hybrid LBA/LCMS & regulatory agencies’ inputs on bioanalysis, biomarkers and immunogenicity)